CHMP recommends EU conditional approval of Roche ’s Alecensa (alectinib) for people with previously treated ALK-positive NSCLC
Roche announced today that the European Medicines Agency (EMA) for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Alecensa ® (alectinib) for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | European Medicines Agency (EMA) | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals